Stephen Ubl

Stephen Ubl is president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America's leading biopharmaceutical research companies.

Ubl leads PhRMA's work preserving and strengthening a healthcare and economic environment that encourages medical innovation, new drug discovery, and access to life-saving medicines.

Previously, Ubl served as president and CEO of medical technology association AdvaMed. At AdvaMed Ubl helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. He led the industry’s staunch defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry.

Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation).

He is routinely recognized as one of Washington’s most effective advocates, and, in 2017, was named for the second year in a row to Modern Healthcare’s “100 Most Influential People in Healthcare.” In 2016, he was named a Top Lobbyist by The Hill and a top health influencer by Medical Marketing & Media and PR Week magazines.

Prior to AdvaMed, Ubl was vice president of legislation for the Federation of American Hospitals. He began his Washington career on Capitol Hill.